Does MAP kinase inhibition with CNI-1493 prevent post-ERCP pancreatitis?

Gepubliceerd: 09-09-2005 Laatst bijgewerkt: 18-08-2022

Prophylactic administration of p38 MAP/JNK kinase inhibitor may decrease the incidence of post-ERCP pancreatitis through inhibition of the pro-inflammatory cytokines IL-1, IL-6, TNF and MIP. In animal studies CNI-1493 or related compounds have been...

Ethische beoordeling	Positief advies
Status	Werving gestopt
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON23715

Bron
NTR

Verkorte titel
CNI study

Aandoening

Patients with a need to undergo ERCP and a relatively high risk to develop post-ERCP pancreatitis.

Ondersteuning

Primaire sponsor: Cytokine PharmaSciences, Inc
King of Prussia, PA
United States of America

Overige ondersteuning: N/A

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Does administration of CNI-1493 decrease the incidence of post ERCP pancreatitis in high risk patients undergoing ERCP?

Toelichting onderzoek

Achtergrond van het onderzoek

Acute pancreatitis can be due to many causes including biliary stone disease, alcohol abuse, and medication. It can also be caused by medical intervention through manipulation of area of the ampulla of Vater and diagnostic and/or therapeutic interventions in the biliary and pancreatic ductal system (endoscopic retrograde cholangiopancreaticography (ERCP)).

The overall reported incidence of post-ERCP pancreatitis is 7%, in certain subgroups with an increased risk this goes up to 20%. Local damage (temporary increased ductal pressure due to contrast injection andor oedema due to manipulations) is followed by a local inflammatory response (TNF, IL-1, IL-6). In 80% of cases post-ERCP pancreatitis runs a relatively benign course with a few day o (severe) abdominal pain and a uneventful recovery. In other cases a severe pancreatitis develops with necrosis of parenchymal pancreatitis tissue (with or without infection) and a systemic inflammatory response syndrome (SIRS).

In the latter group morbidity and mortality are high. Of these patients 25% will die. Recently, a group of synthetic guanylhydrazone compounds have been developed and one of its representatives CNI-1493 (a p38 MAP kinase inhibitor) proved to be a very powerful inhibitor of TNF-alpha. In addition, CNI-1493 inhibits a host of other macrophage induced pro-inflammatory cytokines (IL-1, IL-6, MIP-1ƒÑ en MIP-1ƒÒ).

The primary question that we want to address is whether it is possible with the prophylactic administration of CNI-1493 to lower the incidence of post-ERCP pancreatitis.

The study is double blind and randomized. Patients with a increased risk to develop post-ERCP pancreatitis will be randomized between prophylactic administration of CNI-1493 (50 mg IV) and placebo.

Patients will be follow-up for 48 hours. Blood samples will be taken at regular intervals for amylase and lipase (and CRP, IL-6, IL-1, TNF, IL-8). Clinical symptoms such as pain are quantified by means of VAS scores and noted.
The primary endpoint is the incidence of post-ERCP pancreatitis.
Other (secondary) endpoints include morbidity, mortality, incidence of post-ERCP hyper hyperamylasemia, serum concentrations of cytokines/chemokines.

Doel van het onderzoek

Prophylactic administration of p38 MAP/JNK kinase inhibitor may decrease the incidence of post-ERCP pancreatitis through inhibition of the pro-inflammatory cytokines IL-1, IL-6, TNF and MIP. In animal studies CNI-1493 or related compounds have been shown to reduce the severity of experimental pancreatitis and pancreatitis associated lung injury.

Onderzoeksopzet

N/A

Onderzoeksproduct en/of interventie

Single infusion of CNI-1493 (50 mg IV or placebo IV (randomized, double blind) 1 h prior to start of ERCP.

Contactpersonen

Publiek

Academical Medical Center (AMC),
Department of Gastroenterology-Hepatology (MDL),
P.O. Box 22660
M.J. Bruno
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands

Wetenschappelijk

Academical Medical Center (AMC),
Department of Gastroenterology-Hepatology (MDL),
P.O. Box 22660
M.J. Bruno
Meibergdreef 9
Amsterdam 1100 DD
The Netherlands

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

1. Included are all patients who do not fit the exclusion criteria and will undergo an ERCP with the intention to:

a. Cannulate and visualize the pancreatic duct;

b. Perform therapeutic procedures (e.g. stenting, balloon dilatation, sphincter manometry, precut papillotomy, stone extraction, (intra-luminal) endosonography, ESWL and dilatation.) in the pancreatic duct, common bile duct or left and right hepatic ducts.

2. Patients must agree to use acceptable means of birth control for at least 3 months after the procedure;

3. Patients must sign informed consent.

Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

1. Diagnostic ERCP (low risk);

2. Active pancreatitis at time of ERCP (confounding);

3. Severe abdominal pain pre ERCP (confounding);

4. Age < 18 years (contra indication);

5. Known or suspected pregnancy or breast-feeding (contra indication);

6. ERCP for stent exchange in malignant disease (low risk);

7. Severe chronic pancreatitis (low risk);

8. Kidney failure, ie, serum creatinine > 2.0 mg/dl (> 180 ƒÝM) (any state, contra indication);

9. Other anti-TNF therapy (eg, infliximab) within 8 weeks of intended study treatment.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Parallel
Toewijzing:	Gerandomiseerd
Blindering:	Dubbelblind
Controle:	Placebo

Deelname

Nederland

Status:	Werving gestopt
(Verwachte) startdatum:	01-03-2002
Aantal proefpersonen:	270
Type:	Werkelijke startdatum

Ethische beoordeling

Positief advies

Datum:	09-09-2005
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL161
NTR-old	NTR196
Ander register	: N/A
ISRCTN	ISRCTN26235881

Resultaten

Samenvatting resultaten
Gastrointest Endosc. 2008 Aug;68(2):246-54. Epub 2008 May 2.